Lumateperone clinical trials
Also written ITI-007 and Caplyta.
ClinicalTrials.gov finds 38 studies for lumateperone. How that becomes 38 here
Every study that search finds has been read, to see whether and how it gives lumateperone. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 38Found by its intervention search · See all 38 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 31 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- 38Give lumateperone to participants
- 38Test it: the count on this site
Get an email when these change. Save the lumateperone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Dec 2019 · CAPLYTA · NDA 209500 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
38 studies that test it; most in 2024 (10)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 5 |
| 2023 | 3 |
| 2024 | 10 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 12
Intra-Cellular Therapies, Inc. (26) · University of Chicago (1) · Watim Medical & Dental College (1) · Future Options Research, LLC (1) · University of Texas at Austin (1) · Eric Lenze (1) · Jason Careri (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7, 4 in phase 3
Studies that test lumateperone, phase 3 first.
- Dec 2026Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.Phase 3 · Louisiana State University Health Sciences Center Shreveport
- Apr 2027Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPhase 3 · Intra-Cellular Therapies, Inc.
- Jun 2027Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric PatientsPhase 3 · Intra-Cellular Therapies, Inc.
- Jun 2027Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric PatientsPhase 3 · Intra-Cellular Therapies, Inc.
- Dec 2026Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With SchizophreniaPhase 4 · University of Massachusetts, Worcester
- Mar 2027This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse EffectsPhase 4 · Watim Medical & Dental College
- Jul 2027Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency DisorderPhase 2 · CSTrials Inc.
Studies
Open first, then newest update. How each study uses lumateperone has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 38
- A Study of Lumateperone Versus Placebo in Participants With Major Depressive DisorderNot yet recruitingPhase 3Intra-Cellular Therapies, Inc.NCT07747389In major depressive disorderWritten as LumateperoneReport a problem
- Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric PatientsRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT06706674For irritability in autism in childrenReport a problem
- Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT05850689Added on in major depressive disorderWritten as LumateperoneReport a problem
- Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT06229210Safety in children with schizophrenia, bipolar disorder or autismWritten as LumateperoneReport a problem
- Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT06372964In children with bipolar depressionWritten as LumateperoneReport a problem
- Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric PatientsRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT06690398For irritability in autism in childrenReport a problem
- This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse EffectsNot yet recruitingPhase 4Watim Medical & Dental CollegeNCT07676669Against cariprazine in bipolar I depressionWritten as LumateperoneReport a problem
- Lumateperone Added to Antidepressant Therapy in Adults With Major Depressive Disorder Experiencing Emotional BluntingNot yet recruitingPhase 4Future Options Research, LLCNCT07824206Added to antidepressants for emotional bluntingReport a problem
- Lumateperone for Late-Life DepressionRecruitingPhase 3Eric LenzeNCT07623135In late-life depressionWritten as LumateperoneReport a problem
- Caplyta Versus Placebo for Adults With Social Anxiety DisorderRecruitingPhase 4Jason CareriNCT07799493In social anxiety disorderWritten as Lumateperone 42 mgReport a problem
- The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar DepressionRecruitingPhase 4Massachusetts General HospitalNCT07699445On obesity and ageing markers in bipolar depressionWritten as Lumateperone 42 mgReport a problem
- Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency DisorderRecruitingPhase 2CSTrials Inc.NCT07734103In childhood-onset stutteringWritten as Lumateperone (ITI-007)Report a problem
- Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With SchizophreniaRecruitingPhase 4University of Massachusetts, WorcesterNCT06174116Added to clozapine, on metabolic effectsWritten as LumateperoneReport a problem
- Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life AbuseNot yet recruitingPhase 4University of Texas at AustinNCT07369115Added on in depression with early-life abuseWritten as Lumateperone 42 mgReport a problem
- Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.RecruitingPhase 3Louisiana State University Health Sciences Center ShreveportNCT06482554Against continuing risperidone, for apathy in psychosisWritten as Lumateperone 42 mgReport a problem
- Lumateperone for the Prevention of Relapse in Patients With SchizophreniaCompletedPhase 3Intra-Cellular Therapies, Inc.NCT04959032On the US labelTo prevent relapse in schizophreniaWritten as Lumateperone 42 mgReport a problem
- Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective DisorderCompletedPhase 1Intra-Cellular Therapies, Inc.NCT06627413Long-acting injectable formulations in schizophreniaWritten as Lumateperone CapsuleReport a problem
- Caplyta in Borderline Personality DisorderCompletedPhase 2University of ChicagoNCT05356013In borderline personality disorderWritten as CaplytaReport a problem
- Study of Lumateperone in the Acute Treatment of Patients With Bipolar ManiaCompletedPhase 3Intra-Cellular Therapies, Inc.NCT06462586In acute bipolar maniaWritten as LumateperoneReport a problem
- Study of Lumateperone in the Treatment of Patients With Bipolar ManiaCompletedPhase 3Intra-Cellular Therapies, Inc.NCT06462612In bipolar maniaWritten as LumateperoneReport a problem
See all 38 studies that test lumateperone →
Behind its US label · 7 — the studies the FDA label of CAPLYTA describes
From the Clinical Studies section of CAPLYTA (2025-06), as openFDA has it. A study the site does not hold is left out.
- Study of a Novel Antipsychotic ITI-007 in SchizophreniaCompletedPhase 2Intra-Cellular Therapies, Inc.NCT01499563Report a problem
- A Trial to Assess the Antipsychotic Efficacy of ITI-007CompletedPhase 3Intra-Cellular Therapies, Inc.NCT02282761Report a problem
- Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar DepressionCompletedPhase 3Intra-Cellular Therapies, Inc.NCT02600507Report a problem
- Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted GloballyCompletedPhase 3Intra-Cellular Therapies, Inc.NCT03249376Report a problem
- Lumateperone for the Prevention of Relapse in Patients With SchizophreniaCompletedPhase 3Intra-Cellular Therapies, Inc.NCT04959032Report a problem
- Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedPhase 3Intra-Cellular Therapies, Inc.NCT04985942Report a problem
- Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedPhase 3Intra-Cellular Therapies, Inc.NCT05061706Report a problem
Tested on its own · 32 — no other medicine in its arm
- A Study of Lumateperone Versus Placebo in Participants With Major Depressive DisorderNot yet recruitingPhase 3Intra-Cellular Therapies, Inc.NCT07747389In major depressive disorderWritten as LumateperoneReport a problem
- Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT05850689Added on in major depressive disorderWritten as LumateperoneReport a problem
- Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT06229210Safety in children with schizophrenia, bipolar disorder or autismWritten as LumateperoneReport a problem
- Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT06372964In children with bipolar depressionWritten as LumateperoneReport a problem
- This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse EffectsNot yet recruitingPhase 4Watim Medical & Dental CollegeNCT07676669Against cariprazine in bipolar I depressionWritten as LumateperoneReport a problem
- Lumateperone for Late-Life DepressionRecruitingPhase 3Eric LenzeNCT07623135In late-life depressionWritten as LumateperoneReport a problem
- Caplyta Versus Placebo for Adults With Social Anxiety DisorderRecruitingPhase 4Jason CareriNCT07799493In social anxiety disorderWritten as Lumateperone 42 mgReport a problem
- The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar DepressionRecruitingPhase 4Massachusetts General HospitalNCT07699445On obesity and ageing markers in bipolar depressionWritten as Lumateperone 42 mgReport a problem
- Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency DisorderRecruitingPhase 2CSTrials Inc.NCT07734103In childhood-onset stutteringWritten as Lumateperone (ITI-007)Report a problem
- Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With SchizophreniaRecruitingPhase 4University of Massachusetts, WorcesterNCT06174116Added to clozapine, on metabolic effectsWritten as LumateperoneReport a problem
- Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life AbuseNot yet recruitingPhase 4University of Texas at AustinNCT07369115Added on in depression with early-life abuseWritten as Lumateperone 42 mgReport a problem
- Lumateperone for the Prevention of Relapse in Patients With SchizophreniaCompletedPhase 3Intra-Cellular Therapies, Inc.NCT04959032On the US labelTo prevent relapse in schizophreniaWritten as Lumateperone 42 mgReport a problem
- Caplyta in Borderline Personality DisorderCompletedPhase 2University of ChicagoNCT05356013In borderline personality disorderWritten as CaplytaReport a problem
- Study of Lumateperone in the Acute Treatment of Patients With Bipolar ManiaCompletedPhase 3Intra-Cellular Therapies, Inc.NCT06462586In acute bipolar maniaWritten as LumateperoneReport a problem
- Study of Lumateperone in the Treatment of Patients With Bipolar ManiaCompletedPhase 3Intra-Cellular Therapies, Inc.NCT06462612In bipolar maniaWritten as LumateperoneReport a problem
- Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum DisorderCompletedPhase 1Intra-Cellular Therapies, Inc.NCT06557902In children with autismWritten as Lumateperone 10.5 mg capsuleReport a problem
- Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective DisorderCompletedPhase 1Intra-Cellular Therapies, Inc.NCT04779177In children and adolescents with schizophreniaWritten as Lumateperone 42 mgReport a problem
- Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar DepressionCompletedPhase 3Intra-Cellular Therapies, Inc.NCT02600494Alone in bipolar depression (Study 401)Written as ITI-007 (Lumateperone)Report a problem
- An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedPhase 3Intra-Cellular Therapies, Inc.NCT05061719Open label, added on in major depressive disorderWritten as LumateperoneReport a problem
- Study of a Novel Antipsychotic ITI-007 in SchizophreniaCompletedPhase 2Intra-Cellular Therapies, Inc.NCT01499563On the US labelAgainst placebo and risperidone in schizophrenia, phase 2Written as ITI-007Report a problem
Showing 20 of 32. See all 32 →
Tested with established drugs · 1 — they are given beside it
- Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective DisorderCompletedPhase 1Intra-Cellular Therapies, Inc.NCT06627413Long-acting injectable formulations in schizophreniaWritten as Lumateperone CapsuleReport a problem
Tested in a combination · 5 — another drug in the study is under test too
- Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric PatientsRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT06706674For irritability in autism in childrenReport a problem
- Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric PatientsRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT06690398For irritability in autism in childrenReport a problem
- Lumateperone Added to Antidepressant Therapy in Adults With Major Depressive Disorder Experiencing Emotional BluntingNot yet recruitingPhase 4Future Options Research, LLCNCT07824206Added to antidepressants for emotional bluntingReport a problem
- Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.RecruitingPhase 3Louisiana State University Health Sciences Center ShreveportNCT06482554Against continuing risperidone, for apathy in psychosisWritten as Lumateperone 42 mgReport a problem
- Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With SchizophreniaCompletedPhase 1Intra-Cellular Therapies, Inc.NCT04709224Its long-acting injectable in schizophreniaReport a problem
Codes
What other systems call lumateperone · ClinicalTrials.gg INT001287
- MeSH (NLM) C000705749lumateperoneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 70BSQ12069LUMATEPERONEConfirmed FDA, NLM
- RxNorm 2275602One source FDA
- NCI Thesaurus C166975LumateperoneOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705749 | lumateperone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 70BSQ12069 | LUMATEPERONE | Confirmed FDA, NLM |
| RxNorm | 2275602 | — | One source FDA |
| NCI Thesaurus | C166975 | Lumateperone | One source FDA |
Also registered as lumateperone tosylate (UNII JIE88N006O · RxNorm 2275731).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.